Full Text View
Tabular View
No Study Results Posted
Related Studies
Phase I Study of OSI-930 and Erlotinib in Cancer Tumors
This study is ongoing, but not recruiting participants.
Study NCT00603356   Information provided by OSI Pharmaceuticals
First Received: December 26, 2007   Last Updated: May 21, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Advanced Solid Tumors
Interventions listed in this trial
OSI-930 and erlotinib
Additional drug interventions recognized in this trial
Erlotinib
More general drug interventions related to this trial
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Protein Kinase Inhibitors
Sponsors listed in this trial
OSI Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services